Piper Sandler analyst Adam Maeder raised the firm’s price target on Inari Medical (NARI) to $52 from $50 and keeps a Neutral rating on the shares. The firm notes Inari reported record high revenue in Q3 with $153.4M, which topped both consensus and its model. Piper was encouraged to see that the beat was driven by the company’s U.S. core VTE franchise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: